BioNTech Holds Presser on Coronavirus Vaccine Programme

© REUTERS / BioNTech SE 2020, all rights resA dose of the coronavirus disease (COVID-19) vaccination of BioNTech and Pfizer is pictured in this undated handout photo, as Britain became the first western country to approve a COVID-19 vaccine, in Mainz, Germany
A dose of the coronavirus disease (COVID-19) vaccination of BioNTech and Pfizer is pictured in this undated handout photo, as Britain became the first western country to approve a COVID-19 vaccine, in Mainz, Germany - Sputnik International
Subscribe
US
India
Global
The UK government earlier in the day authorised the use of the coronavirus vaccine developed by German biopharmaceutical company BioNTech and its US partner Pfizer.

Sputnik goes live from Mainz, Germany, as BioNTech SE is holding a press conference on the subject of the COVID-19 vaccine development programme of its lead vaccine candidate BNT162b2, developed with Pfizer.​

In November, BioNTech and Pfizer announced that their vaccine had 95 percent efficacy, according to the final trial analysis.

The company had initiated additional rolling submissions across the globe including in the United States, Australia, Canada, and Japan, and plans to submit applications to other regulatory agencies around the world.

Follow Sputnik's Feed to Find Out More

Newsfeed
0
To participate in the discussion
log in or register
loader
Chats
Заголовок открываемого материала